Journal Article

The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group

Nicosia Luca, Trodella Luca Eolo, Sepulcri Matteo, Ognibene, Lucia, Bortolus, Roberto, Scorsetti Marta, Timon Giorgia, Livi Lorenzo, Jereczek-Fossa, Barbara Alicja, Franzese Ciro, Marvaso Giulia, Ramella, Sara, Alongi Filippo, Borghetti Paolo, Matrone Fabio, Vinciguerra Annamaria, Francolini Giulio, Arcangeli Stefano, Corti Luigi, Magrini, Stefano Maria

2021

Overview

Although systemic therapy represents the standard of care for polymetastatic kidney cancer, stereotactic body radiation therapy (SBRT) may play a relevant role in the oligometastatic setting. We conducted a multicenter study including oligometastatic kidney cancer treated with SBRT. We retrospectively analyzed 207 patients who underwent 245 SBRT treatments on 385 lesions, including 165 (42.9%) oligorecurrent (OR) and 220 (57.1%) oligoprogressive (OP) lesions. Most common sites were lung (30.9%) for OR group, and bone (32.7%) for OP group. Among 78 (31.8%) patients receiving concomitant systemic therapy, sunitinib (61.5%) and pazopanib (15.4%) were the most common for OR patients, while sunitinib (49.2%) and nivolumab (20.0%) for OP patients. End points were local control (LC), progression free survival (PFS), overall survival (OS), time to next systemic therapy (TTNS) and toxicity. Median follow-up was 18.6 months. 1, 2 and 3-year LC rates were 89.4%, 80.1% and 76.6% in OR patients, and 82.7%, 76.9% and 64.3% in those with OP, respectively. LC for OP group was influenced by clear cell histology (p = 0.000), total number of lesions (p = 0.004), systemic therapy during SBRT (p = 0.012), and SBRT dose (p = 0.012). Median PFS was 37.9 months. 1, 2- and 3-year OS was 92.7%, 86.4% and 81.8%, respectively. Median TTNS was 15.8 months for OR patients, and 13.9 months for OP patients. No grade 3 or higher toxicities were reported for both groups. SBRT may be considered an effective safe option in the multidisciplinary management of both OR and OP metastases from kidney cancer.

• Publisher: Springer Nature B.V
• Subject: Cancer / Cancer therapies / Histology / Immunotherapy / Inhibitor drugs / Kidney cancer / Kidneys / Lesions / Metastases / Metastasis / Monoclonal antibodies / Patients / Radiation therapy / Survival / Toxicity